34 results about "Vascular Calcifications" patented technology

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHR1, also known as parathyroid hormone / parathyroid hormone related protein receptor. The PTHR1 compounds are derived from the intracellular loops and domains of the PTHR1 receptor. The invention also relates to the use of these PTHR1 receptor compounds and pharmaceutical compositions comprising the PTHR1 receptor compounds in the treatment of diseases and conditions associated with PTHR1 receptor modulation, such as osteoporosis; humoral hypercalcemia of malignancy; osteolytic and osteoblastic metastasis to bone; primary and secondary hyperparathyroidism associated increase in bone absorption; vascular calcification; psychiatric disorders and cognitive disorders associated with hyperparathyroidism; dermatological disorders; and excess hair growth.

An apparatus for treating cardiac valve and vascular calcification and a method of using the same are disclosed. The apparatus includes a shock wave transmitter for receiving a voltage / current pulse to generate a shock wave; a balloon sealingly connected to one end of the shock wave emitter such that an electrolyte liquid conducting the shock wave flows within the shock wave emitter and the balloon; a developing member located on the shock wave emitter and / or the balloon. As describe above, th application apparatus can use shock wave to soften the calcified area, and the treatment of the calcify area can be completed quickly and effectively.

The present invention relates to methods of decreasing, inhibiting, or preventing vascular calcification in subjects by administering IL-1 inhibitors. IL-1 inhibitors useful in this invention include anakinra, IL-1 antibodies, IL-1 RI antibodies, IL-1 trap molecules, soluble IL-1 receptors, and anti-IL-1 / IL-1R peptides and peptibodies.

The invention provides a discharge-controllable shock wave balloon catheter system which comprises a shock wave treatment host, a balloon, a catheter and a plurality of electrode pairs, wherein one end of the catheter penetrates through the balloon; the other end of the catheter is connected with the shock wave treatment host, and the electrode pair is contained in the balloon and installed on the catheter. The shock wave treatment host comprises a plurality of pulse switch modules, the single electrode pairs are electrically connected with the single pulse switch modules in a one-to-one correspondence mode, or the plurality of electrode pairs are independently electrically connected with the same pulse switch module. According to the shock wave balloon catheter system, by arranging the electrode pairs of different sizes, precise treatment of calcified blood vessels can be achieved easily; herein, the multiple electrode pairs are not connected in series, the magnitude and frequency of shock wave energy released by each electrode pair can be independently controlled, synchronous high-voltage pulse discharge can be achieved and asynchronous high-voltage pulse discharge can also be achieved, so that the flexibility of a discharge control mechanism is improved, the discharge efficiency is improved, and the surgical treatment time of vascular calcification is shortened.

The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and / or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and / or treatment.

The invention belongs to the technical field of medicines, particularly relates to application of cyanidin in prevention and treatment of vascular calcification, and discloses application of cyanidin in prevention and treatment of vascular calcification in order to find a new compound for treatment of VC and provide a better prevention and treatment scheme for VC patients. The cyanidin treatment is carried out in the calcified male mouse induced by high Pi and in the calcification induction process of HASC, and it is found that cyanidin can relieve vascular calcification and is expected to be applied to prevention and treatment of vascular calcification diseases. The invention not only provides a new application of cyanidin, but also provides a new thought for treating vascular calcification.

The invention provides a balloon system and a vascular calcification treatment device, the balloon system comprises a catheter, one end of the catheter is provided with a beam expander, the other end of the catheter is provided with an injection interface and a laser interface, the catheter is sleeved with a balloon, and the catheter is internally provided with a first optical fiber bundle, a second optical fiber bundle, a balloon pressurizing channel and a guide wire channel; two ends of the first optical fiber bundle are respectively connected with the laser interface and the beam expander; one end of the balloon pressurizing channel is communicated with the injection interface, and the other end of the balloon pressurizing channel is communicated with the balloon; a cavitation bubble groove is formed in the catheter and communicated with the balloon, one end of the second optical fiber bundle is connected with the laser interface, and the other end of the second optical fiber bundle is located on one side of the cavitation bubble groove. According to the balloon system, forward ablation and lateral calcified tissue treatment are completed on one catheter at the same time, the operation time of doctors is shortened, and the treatment cost of the doctors is reduced.

The invention relates to a current peak detection device, a high voltage generator and vascular calcification treatment equipment. The current peak detection device comprises a PCB Rogowski coil, a sampling resistor, a signal amplification circuit, an integration and voltage holding circuit and a microcontroller, wherein the PCB Rogowski coil is used for sensing a current signal in a circuit to be detected and obtaining a corresponding induced electromotive force; the sampling resistor is connected with the PCB Rogowski coil, the signal amplification circuit is connected with the sampling resistor, the integration and voltage holding circuit is connected with the signal amplification circuit; the microcontroller is connected with the integration and voltage holding circuit and used for conducting ADC sampling on the maximum value of a voltage signal, and the current peak value of the current signal in the circuit to be detected is obtained according to the ADC sampling data and preset current calibration data. According to the invention, real-time monitoring of the pulse current can be realized, the current peak value of the pulse current can be accurately detected, an original high-voltage discharge loop is not influenced, and the device has the advantages of high safety, fast response speed, stable process, high consistency and low cost.

The present invention provides methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis treatment. In a specific embodiment, the present disclosure provides a method comprising administering to a patient during peritoneal dialysis treatment a dialysis solution comprising a therapeutically effective amount of pyrophosphate ranging between about 30 μM and about 400 μM. Formulation of dialysis solutions according to the dosage range claimed in the present disclosure allows delivery of therapeutic amounts of pyrophosphate to peritoneal dialysis patients.

A method of treating or preventing vascular calcification in a patient by administering L-ascorbic acid or ascorbate to the patient and a pharmaceutical composition containing at least one statin and L-ascorbic acid or ascorbate in a dosage form that allows for the concomitant administering of the at least one statin and L-ascorbic acid or ascorbate to a patient.

A shockwave device for treating heart valve or vascular calcification, includes a guiding tip and a plurality of balloons. At least two balloons of the plurality of balloons are connected to the guiding tip. At least one balloon of the plurality of balloons includes: at least one balloon body; at least one through hole through which liquid for transmitting shockwaves is filled into the balloon; and at least one shockwave generator for receiving electrical voltage / electrical current pulses to generate shockwaves. The shockwave generator includes at least one electrode cable and at least one electrode probe. The shockwave device could inhibit attenuation of shockwaves during transmitting. A method for treating heart valve or vascular calcification of an animal has been provided.

The inventors demonstrate that the phosphatase and hydrolase domains of soluble epoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.

A method of treating or inhibiting a kidney disorder can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for the kidney disorder (treat disease) and / or inhibit development of the kidney disorder (prophylactic). The kidney disorder can be selected from the group consisting of chronic kidney disease mineral bone disorder (CKD-MBD), calciphylaxis, nephrogenic systemic fibrosis (NSF), end stage renal disease, and combinations thereof. The therapy can include inhibiting vascular calcification (VC), hard tissue calcification, soft tissue calcification, mineralization, or combinations thereof in the subject with the ASARM peptide. A method of inhibiting mineralization can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for inhibit mineralization in the subject. A method of treating hyperphosphatemia can include administering a therapeutically effective amount of the ASARM peptide to a subject to provide a treatment for hyperphosphatemia.

The present invention provides an electrode assembly for a shock wave device, the electrode assembly being provided inside a balloon of the shock wave device, the electrode assembly comprising: a first insulating layer having an elongated hollow structure; an inner electrode; the inner electrode is positioned in the first insulating layer; a first conductor provided on at least a portion of an outer peripheral surface of a tip of the first insulating layer; and an external electrode disposed on at least a portion of an outer peripheral surface of a base end of the first insulating layer such that an insulating gap is formed between the external electrode and the first conductor. According to the electrode assembly, attenuation of shock waves in the conduction process can be effectively reduced, the service life of the electrode assembly can be effectively prolonged, and therefore the satisfactory treatment effect can be safely and reliably achieved.

The invention discloses a long-acting sustained-release cardiovascular coating material with dual functions of anti-calcification and anti-proliferation and a preparation method thereof; the preparation method is as follows: firstly polishing, cleaning and drying the base material to be modified and modified ; Then place the treated substrate in dopamine solution, react at 10-30°C for 0.5-2h; then put the reacted substrate into biomacromolecule solution, heparin solution and biomacromolecule solution in sequence , respectively soaked for 10 minutes, and then transferred to drug-loaded micelles for soaking for 20 minutes; finally, the soaking step was repeated 1 to 30 times to obtain the final product. Using this method, a cardiovascular coating material with excellent mechanical properties and sustained drug release can be prepared. By loading the drug-loaded micelles with anti-vascular calcification drugs and anti-vascular smooth muscle hyperplasia drugs, it can effectively support the cardiovascular system. Anti-calcification and anti-proliferation properties of vascular stent coating materials.

The invention discloses an application of a GPR31 inhibitor in preparation of a medicine for preventing and treating vascular calcification. The vascular calcification is a common pathological expression commonly existing in atherosclerosis, hypertension, diabetes, vasculopathy, chronic kidney disease, senescence and the like. According to the invention, the inhibition effect on the GPR31 gene is realized by utilizing siGPR31, and smooth muscle cell osteogenic differentiation induced by a high phosphate culture medium can be remarkably treated, so that the GPR31 inhibitor has a relatively wide application prospect in treatment of vascular calcification.

The present disclosure relates to a hemodialysis membrane for the treatment of vascular calcification in hemodialysis patients, especially in chronic hemodialysis patients. The present disclosure further relates to methods of treating vascular calcification in hemodialysis patients, wherein the hemodialysis membrane is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD or that the hemodialysis membrane comprises at least one hydrophobic polymer and at least one hydrophilic polymer and has a MWRO of between 8.5 kD and 14.0 kD and a MWCO of between 55 kD and 130 kD.

The present invention belongs to the technical field of medicine, and relates to the new application of κ-opioid receptor agonist U50,488H, and more specifically, relates to the application of κ-opioid receptor agonist U50,488H in the preparation of drugs for treating vascular calcification. Experiments have proved that its mechanism of inhibiting vascular calcification is: by reducing the expression of PFKFB3, and then inhibiting the level of glycolysis, thereby inhibiting the calcification of VSMCs induced by high phosphorus. The research results provide a potential drug target for the clinical treatment of vascular calcification and treatment strategies.

The invention relates to a chain type coronary stent suitable for coronary artery tortuosity angulation and particularly lesion accompanied with vascular calcification. The stent consists of a plurality of closed waveform ring-shaped units which form a cylindrical structure; axial connection in the movement direction of a guide wire is realized between the ring-shaped units by connecting assemblies; the connecting assemblies comprise rigid connecting assemblies and elastic connecting assemblies; the stent adopts every two to four ring-shaped units to form one unit group; the adjacent ring-shaped units in each unit group are connected by the rigid connecting assemblies; the unit groups are connected by the elastic connecting assemblies. According to the stent disclosed by the invention, by arranging the elastic connecting assemblies between the ring-shaped units, higher passing ability is realized under the condition of not changing the thickness between each two ring-shaped units; moreover, the characteristic requirements of radial intensity, fatigue durability, trackability, propelling movement, perspectivity, elastic return and the like of the stent are kept.

The invention discloses a balloon dilatation catheter which comprises a pushing tube, an inner tube and a balloon, the inner tube is arranged at the far end of the pushing tube, and the outer surface of the inner tube is sleeved with the balloon; wherein the pushing tube is formed by blending and extruding polylaurolactam and polyether block polyamide. The pushing tube of the balloon dilatation catheter has reliable supporting performance and good flexibility and can penetrate tortuous blood vessels, calcified blood vessels and long-section occluded blood vessels, and the use performance is improved.

The invention discloses a plasma marker, a primer pair and a kit for a diagnosis of vascular calcification and an application. The invention discloses a plasma miRNA marker miR-32-5p used for the diagnosis of the vascular calcification. The marker and primers thereof can be used for preparing a diagnostic kit which is used for the clinical diagnosis, prevention and detection of the vascular calcification.

The invention belongs to the technical field of angiosteosis treatment and particularly relates to an application of iron sucrose to preparation of a drug for treating angiosteosis induced by hyperphosphatemia. Hyperphosphatemia causes an oxidative stress injury in a vascular smooth muscle cell to induce phenotypic transformation from the vascular smooth muscle cell into an osteoblast and to finally develop into angiosteosis. In experiments of the invention, it is found that the iron sucrose can interfere with the transmembrane transport of inorganic phosphorus in blood, inhibit the expressionof a phosphorus transmembrane transporter and antagonize the oxidative stress injury induced by the hyperphosphatemia, so as to play a role in treating, relieving or inhibiting the angiosteosis induced by the hyperphosphatemia.

The invention relates to a stent for vascular calcification modeling and a preparation method and application thereof, and belongs to the technical field of medical instruments. The invention provides a stent for vascular calcification modeling, the stent for vascular calcification modeling comprises a first stent, a second stent and a third stent, the second stent sleeves the first stent, the diameter of the second stent is smaller than that of the first stent, the third stent sleeves the second stent, the diameter of the third stent is smaller than that of the first stent, and the diameter of the third stent is smaller than that of the first stent. The diameter of the third bracket is smaller than or equal to that of the second bracket; after being released, the stent for vascular calcification modeling shows a dog bone shape with poor middle expansion, so that an artificial 360-degree annular calcification lesion is formed, and the stent has a great application prospect in coronary atherectomy operation training.

The inventors demonstrate that the phosphatase and hydrolase domains of soluble expoxide hydrolase (sEH) regulate the cardiovascular calcification process and revealed that inhibition of the phosphatase domain of sEH could represent a new pharmacological target in the prevention of cardiovascular calcification. The present invention thus relates to a therapeutically effective amount of an inhibitor of phosphatase activity of soluble epoxide hydrolase for use in a method of treating cardiovascular calcification in a subject in need thereof.

The invention discloses a biomarker for vascular calcification and application of the biomarker, and relates to the field of biomedicine. The biomarker for vascular calcification is SMARCA4 protein. According to the invention, the SMARC4 protein is used as the biomarker for vascular calcification, is used for early diagnosis or auxiliary diagnosis of vascular calcification, has good sensitivity and specificity, and provides a simple and convenient detection means for early diagnosis or auxiliary diagnosis of vascular calcification.

The subject invention provides molecules, compositions and methods for treating, preventing or ameliorating vascular calcification, for example, medial vascular calcification or intimal atherosclerotic calcification. The subject invention also provides molecules, compositions and methods for treating or preventing a disease associated with vascular calcification. The methods of the subject invention employ relaxin-based and / or epidermal growth factor receptor (EGFR)-based strategies through the use of RXFP1 agonists and / or EGFR inhibitors.